Quality

ADMA Biologics returning Bivigam to market after 3-year absence

After manufacturing issues led ADMA Biologics to pull its primary immune deficiency disease drug Bivigam from the market, it's won a new FDA approval.

Eric Palmer May 13, 2019 9:35am

China slaps $1.3B penalty on vaccine scandal culprit

Oct 16, 2018 10:53am

Sanofi's Riboldi talks up new facility's role in flu-shot push

Aug 7, 2017 11:22am

Request for a pause may kill FDA quality metrics proposal

Apr 10, 2017 11:38am

Wockhardt management lambasted by FDA for 'repeated failures'

Mar 8, 2017 3:04pm